Literature DB >> 16037677

Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment.

Silvana Galderisi1, Mario Maj, Brian Kirkpatrick, Paola Piccardi, Armida Mucci, Giordano Invernizzi, Alessandro Rossi, Stefano Pini, Antonio Vita, Paolo Cassano, Paolo Stratta, Giovanni Severino, Maria Del Zompo.   

Abstract

Cognitive and motor deficits have been proposed as markers of abnormal neurodevelopment in schizophrenia and have been associated with genetic liability. In a multicenter study involving 106 subjects, 56 with deficit schizophrenia and 50 with nondeficit schizophrenia, we tested the hypothesis that the catechol-O-methyltransferase (COMT) Val(158)Met polymorphism is associated with cognitive and motor deficits either in schizophrenia as a whole or in its deficit subtype. The COMT Val(158)Met polymorphism shared 6.6% of the executive/attention dysfunction variance in patients with schizophrenia and 15.6% of the motor impairment variance in patients with deficit schizophrenia. These results support the hypothesis that the COMT Val(158)Met polymorphism influences executive functions in schizophrenia and the neuromotor performance in the deficit subtype only.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037677     DOI: 10.1159/000087096

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  16 in total

1.  Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients.

Authors:  Weidong Ji; Ning Li; Kang Ju; Hong Zheng; Chuang Yang; Ping Xu; Silu Chen; Aiai Cao; Xue Chen; Lanting Guo
Journal:  Neurol Sci       Date:  2014-11-04       Impact factor: 3.307

2.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

3.  Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.

Authors:  Hamid Mostafavi Abdolmaleky; Kuang-Hung Cheng; Stephen V Faraone; Marsha Wilcox; Stephen J Glatt; Fangming Gao; Cassandra L Smith; Rahim Shafa; Batol Aeali; Julie Carnevale; Hongjie Pan; Panagiotis Papageorgis; Jose F Ponte; Vadivelu Sivaraman; Ming T Tsuang; Sam Thiagalingam
Journal:  Hum Mol Genet       Date:  2006-09-19       Impact factor: 6.150

4.  COMT genotype, gender and cognition in community-dwelling, older adults.

Authors:  Ruth O'Hara; Elana Miller; Chun-Ping Liao; Nate Way; Xiaoyan Lin; Joachim Hallmayer
Journal:  Neurosci Lett       Date:  2006-10-09       Impact factor: 3.046

Review 5.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

Review 6.  The endophenotype concept in psychiatric genetics.

Authors:  Jonathan Flint; Marcus R Munafò
Journal:  Psychol Med       Date:  2006-09-18       Impact factor: 7.723

7.  Is less really more: Does a prefrontal efficiency genotype actually confer better performance when working memory becomes difficult?

Authors:  Jessica L Ihne; Natalie M Gallagher; Marie Sullivan; Joseph H Callicott; Adam E Green
Journal:  Cortex       Date:  2015-11-14       Impact factor: 4.027

8.  Deficit schizophrenia: an update.

Authors:  Brian Kirkpatrick; Silvana Galderisi
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

9.  Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Jill M Weimer; Jared W Benedict; Yasser M Elshatory; Douglas W Short; Denia Ramirez-Montealegre; Deborah A Ryan; Noreen A Alexander; Howard J Federoff; Jonathan D Cooper; David A Pearce
Journal:  Brain Res       Date:  2007-05-21       Impact factor: 3.252

Review 10.  Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia?

Authors:  S Bender; M Weisbrod; F Resch
Journal:  J Neural Transm (Vienna)       Date:  2007-05-21       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.